نتایج جستجو برای: mutation igvh status

تعداد نتایج: 694113  

Maryam Abdollahi, Maryam Mohammadlou, Parviz Kokhaei,

Chronic lymphocytic leukemia (CLL) is a malignancy of B CD5+cells and is the most common type of leukemia in adults. The disease is more common in men over 50 years in western countries. CLL is associated with defective apoptosis in B cells. CLL was traditionally regarded as a disease that occurs before naïve B cells meet the antigen in the lymph nodes. Laboratory diagnosis requires white blood...

2011
Sang Hyuk Park Hyun-Sook Chi Sook-Kyung Min Young-Uk Cho Seongsoo Jang Chan-Jeoung Park Jung-Hee Lee Je-Hwan Lee Kyoo-Hyung Lee Ho-Joon Im Jong-Jin Seo

BACKGROUND Fms-like tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutation is related to poor prognosis in normal-karyotype acute myeloid leukemia (AML). However, the prognostic significance of the mutation at relapse has not been adequately investigated. We investigated the prognostic significance of the FLT3 ITD mutation at relapse in normal-karyotype AML patients. METHODS We ana...

2015
Yaoyao Ren Yibing Yao Qing Ma Diansheng Zhong

The purpose of this study was to investigate the correlation between EGFR-mutation status and treatment efficacy for advanced lung adenocarcinoma patients. A total of 47 patients receiving erlotinib as first-line therapy were divided into two groups: the EGFR gene mutation group included 19 patients with known EGFR-sensitive mutations, and the EGFR-mutation status-unknown group comprised 28 pat...

Journal: :The Journal of Experimental Medicine 1991
R A Mageed L E MacKenzie F K Stevenson B Yuksel F Shokri B R Maziak R Jefferis P M Lydyard

Human B lymphocytes expressing the CD5 surface antigen (CD5+ B cells) constitute a subset capable of producing polyspecific antibodies recognizing a variety of self antigens. The repertoire of antibodies produced by CD5+ and CD5- B cells is different. However, it is not yet established whether this distribution is reflected in different immunoglobulin variable region gene (IgV) use. Rearrangeme...

2016
Matthias Pauthner Jenny Yeung Chris Ullman Joost Bakker Thierry Wurch Janice M. Reichert Fridtjof Lund-Johansen Andrew R.M. Bradbury Paul J. Carter Joost P.M. Melis

The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015. The latest innovations and advances in antibody research and development were discussed, covering a myriad of antibody-related topics by more than 100 speakers, who were carefully selected by The Antibody Soci...

Journal: :Blood 2014
Steven Marionneaux Larry Smith

A 77-year-old woman presented with cervical adenopathy. A complete blood count was performed: white 1 , and ZAP70 1. Cytogenetics/molecular analysis revealed trisomy 12 and unmutated immunoglobulin heavy chain variable region (IgVH). Positron emission tomography computed tomography showed splenomegaly and widespread adenopathy. WBC differential by digital microscopy (Cellavision) revealed 9% ne...

Journal: :Journal of medical genetics 2003
P Watson S A Narod R Fodde A Wagner J F Lynch S T Tinley C L Snyder S A Coronel B Riley Y Kinarsky H T Lynch

CONTEXT In hereditary cancer syndrome families with an identified cancer associated mutation, mutation testing changes the carrier risk status of the tested person and may change the carrier risk status of relatives. OBJECTIVE This study aimed to describe the change in the distribution of carrier risk status resulting from testing in hereditary breast-ovarian cancer (HBOC) and hereditary non-...

Journal: :Cancer research 2010
Verònica Fernàndez Olga Salamero Blanca Espinet Francesc Solé Cristina Royo Alba Navarro Francisca Camacho Sílvia Beà Elena Hartmann Virginia Amador Luis Hernández Claudio Agostinelli Rachel L Sargent Maria Rozman Marta Aymerich Dolors Colomer Neus Villamor Steven H Swerdlow Stefano A Pileri Francesc Bosch Miguel A Piris Emili Montserrat German Ott Andreas Rosenwald Armando López-Guillermo Pedro Jares Sergi Serrano Elías Campo

Mantle cell lymphoma (MCL) is typically a very aggressive disease with poor outcomes, but some cases display an indolent behavior that might not necessitate treatment at diagnosis. To define molecular criteria that might permit recognition of such cases, we compared the clinicopathologic features, gene expression, and genomic profile of patients who had indolent or conventional disease (iMCL or...

Journal: :Blood 2009
Constantine S Tam Tait D Shanafelt William G Wierda Lynne V Abruzzo Daniel L Van Dyke Susan O'Brien Alessandra Ferrajoli Susan A Lerner Alice Lynn Neil E Kay Michael J Keating

To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had...

Journal: :Current molecular medicine 2006
Alexey V Danilov Olga V Danilova Andreas K Klein Brigitte T Huber

Chronic lymphocytic leukemia (CLL) is unique among malignancies since it represents an accumulation of B-lymphocytes resistant to apoptosis. Several factors are thought to confer this unusual feature to a CLL B-cell. Misbalance between cytoplasmic pro-survival and pro-death molecules, such as Bcl-2, Mcl-1 and alike, appears to be one of the key factors defining B-cell longevity. Autocrine pathw...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید